Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025)

Prelude Therapeutics' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.8 million; the TTM value through Dec 2025 reached $1.8 million, changed N/A, while the annual FY2025 figure was $1.8 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $1.8 million at Prelude Therapeutics.
  • Across five years, Non-Current Deffered Revenue topped out at $1.8 million in Q4 2025 and bottomed at $1.8 million in Q4 2025.